基本信息 产品详情 公司简介 推荐产品
网站主页 RP6530 Tenalisib (RP6530)
  • aladdin 阿拉丁 T414107 Tenalisib (RP6530) 1639417-53-0 99%

aladdin 阿拉丁 T414107 Tenalisib (RP6530) 1639417-53-0 99%

Tenalisib (RP6530)
1639417-53-0
720.90 5mg 起订
925.90 10mg 起订
4402.90 100mg 起订
上海 更新日期:2025-05-16

上海阿拉丁生化科技股份有限公司

VIP3年
联系人:阿拉丁客服
电话:400-6206333拨打
手机:13167063860 拨打
邮箱:anhua.mao@aladdin-e.com

产品详情:

中文名称:
Tenalisib (RP6530)
英文名称:
Tenalisib (RP6530)
CAS号:
1639417-53-0
品牌:
阿拉丁
产地:
上海
保存条件:
-20°C储存
纯度规格:
Moligand™, ≥99%
产品类别:
小分子和化合物库 配体家族
分子式:
C23H18FN5O2
分子量:
415.42
运输条件:
超低温运输
产品规格:
5mg、100mg、10mg
货号:
T414107
是否进口:

中文名:Tenalisib (RP6530)

英文名:Tenalisib (RP6530)

纯度:Moligand™,≥99%

货号:T414107

Cas号:1639417-53-0

存储温度:-20°C储存

运输条件:超低温运输

产品介绍:

Information

Tenalisib (RP6530) is a potent and selective dualPI3Kδ/γinhibitor withIC50values of 24.5 nM and 33.2 nM for PI3Kδ and PI3Kγ, respectively. Its selectivity over α and β isoforms are more than 300-fold and 100-fold, respectively.


Targets

PI3Kδ (Cell-free assay); PI3Kγ (Cell-free assay) 24.5 nM; 33.2 nM


In vitro

RP6530 is a specific dual PI3K δ/γ inhibitor exhibiting several-fold selectivity against the other PI3K isoforms and 245-kinases. RP6530 causes a dose-dependent inhibition (>50% @ 2-7 μM) in growth of immortalized (Raji, TOLEDO, KG-1, JEKO, REC-1) B-cell lymphoma cells. Effect is more pronounced in the DLBCL cell lines, OCI-LY-1 and OCI-LY-10 (>50% inhibition @ 0.1-0.7 μM), and the reduction in viability is accompanied by corresponding inhibition of pAKT with EC50 of 6 & 70 nM respectively. Treatment of patient-derived primary cells with 4 µM RP6530 causes an increase in cell death. Cells in early apotosis (Annexin V+/PI-) are not different between the DMSO blank and RP6530 samples. RP6530 shows potent inhibitory effect on cancer stem cells in ovarian cancer cell lines. Treatment with 1 μM RP6530 results in G2/M arrest in MM-1S and MM-1R lines with very few cells in the SubG0 phase. It also results in a 70−90% inhibition of pAKT in MM-1S and MM-1R cell lines. Potent modulation of inflammatory response by RP6530 contributes to control tumor microenvironment.


In vivo

The predicted T1/2, Cmax, and AUC0-t at 10 mg dose in human are 9.5 h, 14.0 μM, and 342.0 μM respectively. RP6530 has an excellent pharmacokinetic profile with plasma concentrations reaching well above the EC75 at doses as low as 3 mg/kg in rat and dog for 6-12 h. In addition, RP6530 shows >70 and >100% oral bioavailability with a half-life of 2 and 3 h in rat and dog respectively.


Cell Research(from reference)

Cell lines:MM cell lines, namely, MM-1S and MM-1R 

Concentrations:1 μM 

Incubation Time:72 h 


查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/T414107.html


替那西普 (RP6530);SCHEMBL288514 ; BDBM50512870 ; RP 6530

公司简介

上海阿拉丁生化科技股份有限公司是A股上市公司((股票代码:688179),专注于科研试剂的研发、生产和销售,已陆续建立多个工厂和研发中心。作为领军企业,阿拉丁始终坚持质量第一,连续13年被评为“最受欢迎试剂品牌”。 阿拉丁目前常备库存试剂产品品种超过7万种,SKU总数超过46万,产品线涵盖了化学试剂、生化试剂、药靶配体、蛋白质和抗体等多个领域,是国内少数化学试剂到生物试剂全面发展的国产试剂品牌,产品同步发布在我们国内外电商平台。

成立日期 (17年)
注册资本 14130.676万人民币
员工人数 500人以上
年营业额 ¥ 1亿以上
经营模式 工厂,试剂
主营行业 生物化工,化学试剂

Tenalisib (RP6530)相关厂家报价

内容声明
拨打电话 立即询价